Browse Category

Stock Market News 16 October 2025

Battle of the EV Charging Standards: Tesla’s NACS vs. CCS2 vs. CHAdeMO – Who Will Rule the Roads in 2025?

Tesla Stock’s Wild Ride: Soars on Record Deliveries, Then Sags After Budget EV Reveal

Tesla’s mid-October stock action reflects this mix of good news and looming questions. On Oct 16, 2025, TSLA traded roughly flat in the mid-$430s (around $430 by mid-afternoon)reuters.com. That mild move belied a wildly volatile week. After hitting multi-month highs around $453 in early October, Tesla gave back ground on profit-taking. “Tesla’s stock has seesawed sharply,” noted our research: it surged ~5.4% on Oct 6, then plunged 4.5% on Oct 7, jumped again (+5.4%) on Oct 13, and slid ~1.5% on Oct 14ts2.techts2.tech. Most recently, around Oct 10–14 the stock fell on a broad tech selloff and trade worries, then
16 October 2025
Kyivstar (NASDAQ: KYIV) Stock Rockets on 5G Upgrade Plans and Mastercard Tie-Up

Kyivstar (NASDAQ: KYIV) Stock Rockets on 5G Upgrade Plans and Mastercard Tie-Up

Company News and Stock Movement Kyivstar’s share price has been volatile since its historic Nasdaq debut. In August, the IPO raised $178 million (out of a $200M target)reuters.com, valuing the company around $2.6 billion. Initial trading saw a sharp swing: the stock opened around $13–14, then peaked at nearly $16 on Aug. 20 before sliding. By mid-September it had fallen to about $11.25kyivpost.com. ICU Investment Group trader Vitaliy Syvach commented that “after the initial excitement came a more sober assessment” of Kyivstar’s growth prospectskyivpost.com. Indeed, some profit-taking and broader market volatility dampened the early rally. However, new corporate initiatives in October have
16 October 2025
Plug Power Stock Explodes 170% on Analyst Hype & Giant Hydrogen Deal

Plug Power (PLUG) Stock Skyrockets on Hydrogen Hype – Is PLUG a Buy or Bubble?

Stock Rally and Analyst Buzz PLUG’s October rally caught Wall Street’s eye. After slipping for much of 2025, the stock surged in early October as analysts turned bullish and hydrogen demand news broke. For example, H.C. Wainwright on Oct. 3 raised PLUG’s price target from $3 to $7 and maintained a Buy ratingmarketbeat.com, and HSBC upgraded Plug to a “Strong Buy” on Oct. 9marketbeat.com. These upbeat calls came as the company announced its first big electrolyzer delivery in Europe. The result: Plug’s shares nearly doubled since early September, trading around $4.05 by Oct. 14ts2.tech – near a 52-week high –
16 October 2025
NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Nvidia Stock Skyrockets on $100B AI Deal – Will NVDA Hit $320 Target?

Nvidia Stock & Market Performance Nvidia’s stock is trading high in October 2025. It closed at $184.87 on Oct. 15investing.com, up slightly from the prior day, and was around $180–183 in early trading on Oct. 16reuters.com. The week of Oct. 10–16 saw some profit-taking: NVDA hit an intraday high near $195 on Oct. 10investing.com, then retreated into the low-$180s, but remains well above levels from earlier in 2025. Overall, Nvidia is up roughly 30% YTD, vastly outperforming the S&P 500ts2.tech. (For context, the 52-week range is ~$86–195reuters.com.) Trading volumes have been heavy (205–268 million shares daily recentlyinvesting.com), reflecting strong investor interest.
Billionaire-Backed Crypto Bank Approved by Regulators – Are Tech Stocks and Crypto Ready to Soar?

Billionaire-Backed Crypto Bank Approved by Regulators – Are Tech Stocks and Crypto Ready to Soar?

OCC Approval Details The OCC’s approval letter makes Erebor the first new charter since Gould took over in June 2025benzinga.com. In announcing the decision, Gould stressed that innovative banks need not be blocked: “Permissible digital asset activities… have a place in the federal banking system if conducted in a safe and sound manner,” he saidbenzinga.com. This is a notable change of tone from prior OCC leadership. As Benzinga reports, the OCC applied its usual rigorous standards but ultimately concluded Erebor’s plan was sound, making it “the first de novo bank to receive preliminary approval under Gould’s tenure”benzinga.com. Despite the approval,
Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?

Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?

Oracle Stock Today As of Oct. 16, Oracle (NYSE: ORCL) is trading near $304 per share. Investing.com data show ORCL closed at $303.98 on Oct. 16 (up 0.12% for the day)investing.com. This comes after a volatile week: the stock hit an all-time intraday high (~$345.69) on Sept. 10ts2.tech following the AI cloud deal announcements, then pulled back 15–20% by early October on profit-taking and margin concernsts2.techts2.tech. Overall, ORCL is up roughly 70% year-to-date, far outperforming the broader tech sector and even leaving Microsoft and Alphabet in the dustts2.tech. Even mid-month blips (like a 6% drop in early October after a
Western Alliance Bancorp Stock Plunges on First Brands Fallout — Analysts See Upside

Western Alliance Bancorp Stock Plunges on First Brands Fallout — Analysts See Upside

Stock Trends and Recent Moves Western Alliance’s stock has been volatile recently. After rallying through summer, it tumbled in early October. On Oct 8, WAL fell about 4% amid headlines that a Jefferies-managed fund (Point Bonita) held ~$715 million in First Brands receivablests2.techmlq.ai. By Oct 15, WAL closed near $78.84, down ~4% for the dayinvesting.com. Trading volume surged as investors digested the news. A day later (Oct 16), Reuters reported WAL shares were still down ~5.4%reuters.com, despite the bank’s reassurances. Management disclosed it had filed a fraud lawsuit related to one credit and said its “criticized assets” (weak loans) actually
16 October 2025
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwideglobenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to nearly
16 October 2025
Virgin Galactic SPCE Stock Surges on Lawsuit Settlement and Purdue Mission News

Virgin Galactic SPCE Stock Surges on Lawsuit Settlement and Purdue Mission News

Stock Performance & Financials Virgin Galactic’s share price has been in a prolonged slump, though recent news has sparked a bounce. On Oct. 1, 2025 SPCE closed at $3.42 ts2.tech; by Oct. 16 it had rallied to about $4.89 Investing (and was up ~6.3% on the day). The stock traded in a rough range of $3.30–$3.70 through early Oct ts2.tech. Over 2025 the stock is still down roughly one-third (Benzinga reports –33% YTD Benzinga; TS2.Tech data shows ~–42% YTD through Sept ts2.tech), well underperforming the S&P500. SPCE remains extremely volatile (5‑year drawdown ~99% ts2.tech). Financially, Virgin Galactic remains pre‑revenue. Q2
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Koreainvesting.comprnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&Tprnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company advances toward test
J.B. Hunt (JBHT) Stock Soars on Earnings Surprise – Is a Freight Sector Revival Underway?

J.B. Hunt (JBHT) Stock Soars on Earnings Surprise – Is a Freight Sector Revival Underway?

Stock Rally After Earnings Beat J.B. Hunt’s stock rallied hard on Oct. 16. Reuters reported that JBHT shares “rose nearly 16% in early trading on Thursday” (Oct 16) after the company’s cost-cutting drove a stronger-than-expected profitreuters.com. Traders noted a similar jump (about 18%) according to market news on StockTwitsstocktwits.com. The surge pushed JBHT to multi-week highs (roughly mid-$160s per share) as investors reacted to the Q3 results and upbeat comments from analysts. (For context, JBHT had closed around $138.83 on Oct. 15benzinga.com.) The broad market backdrop also helped: easing China trade worries and hopes for Fed rate cuts lifted U.S.
16 October 2025
Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-Octoberstockinvest.us, but the new AI partnership sent them soaring in early trading. By mid-day Oct. 16, various data sites showed WHWK up roughly 50–67% on the sessioninvesting.com. (For comparison, it had already gained ~6.6% on Oct. 15stockinvest.usstocktitan.net.) The sudden jump reflects investor excitement about the Tempus deal, which was announced in a press release on Oct. 16marketscreener.com. The Tempus AI collaboration was officially billed as a “multi-year” partnership to use Tempus’s de-identified, multimodal clinical data to improve Whitehawk’s ADC
16 October 2025
Polestar Stock Skyrockets on Strong EV Sales and New Tech – What’s Next?

Polestar Stock Skyrockets on Strong EV Sales and New Tech – What’s Next?

Recent Stock Performance Polestar’s stock has been volatile in October 2025. After Q3 sales news on Oct. 9, PSNY climbed modestly (Reuters noted a ~+2% premarket risereuters.com), ending around $0.91 on Oct 15. By Oct 16 it was about $0.94investing.com. In contrast, the PSNYW warrants (which had languished at ~$0.20) saw a huge rally to ~$0.35 on Oct 16investing.com. Such warrant spikes often reflect speculative trading and have no immediate impact on company fundamentals, but they signal intense investor interest. StockAnalysis.com confirms PSNYW’s day gain of +76.6% to $0.36 on Oct 16stockanalysis.com. (PSNYW trading is thin and can move wildly.)
United Airlines Stock Takes Off on Travel Boom and Record Revenue Forecast

United Airlines Stock Takes Off on Travel Boom and Record Revenue Forecast

Stock Performance and Recent Trends United’s stock has been climbing steadily heading into the earnings report. It closed around $104.18 on Oct. 15, up about 5% in just two days ts2.tech. This week’s rally built on a broader uptrend – shares have gained roughly 13% over the past quarter and nearly 45% year-on-year ts2.tech. Investors drove the stock higher in anticipation of strong results, aided by optimism across the airline sector. Notably, Delta’s upbeat earnings on Oct. 9 sent airline stocks higher, signaling that strength at one major carrier can lift the group ts2.tech. Market bulls argue that United’s emphasis
16 October 2025
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once
16 October 2025
Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients receiving VCN-01 (an oncolytic adenovirus therapy) plus standard gemcitabine/nab-paclitaxel chemo showed markedly better outcomes than chemo alone. Interim data filed with the SEC reveal VCN-01 improved median overall survival to around 11–14 months versus ~8–11 months for chemo-only patients ts2.tech.
16 October 2025
LOBO EV Tech Rebrands & Sparks Trading Frenzy – What Investors Need to Know

LOBO EV Tech Rebrands & Sparks Trading Frenzy – What Investors Need to Know

Nasdaq Debut and Volatile Trading Lobo’s corporate makeover took effect on Oct. 16, when shareholders’ approval of a name change (dropping the “EV”) and a share reclassification became official tipranks.com. That morning, LOBO opened on Nasdaq at $0.86 and oscillated up to $0.97 before closing flat around $0.93 reuters.com. This frenetic trading came on unusually heavy volume, underscoring heightened interest around the rebrand. The Class A ordinary shares carry the same ticker “LOBO” but signal a new chapter for the company’s capital structure. Management framed the changes as a strategy to “enhance [LOBO’s] market presence” and reflect broader tech ambitions beyond just
Marsh & McLennan’s Q3 Profit Jumps 11% Amid Rebrand to “Marsh” – What’s Next for MMC Stock?

Marsh & McLennan’s Q3 Profit Jumps 11% Amid Rebrand to “Marsh” – What’s Next for MMC Stock?

Q3 2025 Earnings: Solid Growth and an 11% Profit Jump Marsh & McLennan delivered a strong third quarter, topping expectations on both the top and bottom lines. Revenue reached $6.4 billion, up 11% from a year ago (4% on an underlying, constant-currency basis) stocktitan.net stocktitan.net. This was driven by double-digit growth in its core insurance broking unit and steady gains in consulting. The Risk & Insurance Services division (which includes its Marsh insurance brokerage and Guy Carpenter reinsurance arm) saw revenue surge +13% year-over-year to $3.9 billion stocktitan.net, boosted by firm insurance pricing earlier in the year and a rebound in client
16 October 2025
Axon Stock Plunges 8% Amid Market Rally – Analysts See Big Upside Ahead

Axon Stock Plunges 8% Amid Market Rally – Analysts See Big Upside Ahead

Axon Stock Sinks Despite Market Strength Axon shares suffered an unexpected jolt mid-week, falling over 8% in a single session – a steep one-day drop for a typically steady climber. The slide to $644.99 nasdaq.com on Wednesday came with no obvious bad news from the company. In fact, broader market conditions were positive: U.S. stocks rose on the same day on optimism about trade and interest rates ts2.tech. This made Axon’s decline stand out even more, as the stock vastly underperformed major indexes. Technical factors likely played a role. Axon’s plunge pushed it below its 200-day moving average (~$677) nasdaq.com,
16 October 2025
NuScale Stock Skyrockets on Historic SMR Deal – Can GE Vernova Catch Up in the Nuclear Boom?

NuScale Stock Skyrockets on Historic SMR Deal – Can GE Vernova Catch Up in the Nuclear Boom?

NuScale’s Historic SMR Deal Sparks a Nuclear Stock Rally NuScale Power’s stock is on fire after the company secured a massive 6 gigawatt SMR deployment program with the Tennessee Valley Authority (TVA) – “the largest SMR deployment in U.S. history,” according to NuScale ts2.tech. The deal, executed via NuScale’s ENTRA1 Energy venture, will see up to six 77 MWe modular reactors installed in TVA’s service area, enough to power ~4.5 million homes and dozens of data centers ts2.tech. Investors cheered the news: on October 13, SMR shares spiked ~14% intraday, and by mid-week the stock was trading around $55 – roughly 20% higher
16 October 2025

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Go toTop